Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.

Authors:
Di Wang
Di Wang
School of Life Sciences
Tempe | United States
Liankun Ren
Liankun Ren
China-Japan Friendship Hospital
Yicong Lin
Yicong Lin
Capital Medical University
China
Lehong Gao
Lehong Gao
Xuanwu Hospital
Nanjing Shi | China
Yuping Wang
Yuping Wang
Capital Medical University
China

Clin Neurol Neurosurg 2019 Jun 28;181:64-66. Epub 2019 Mar 28.

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; The Beijing Key Laboratory of Neuromodulation, Beijing 100053, China; Center of Epilepsy, Beijing Institute for Brain Disorder, Beijing 100069, China; Department of Pediatrics, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. Electronic address:

The target brain binding site of levetiracetam (LEV) is synaptic vesicle glycoprotein 2A (SV2A). Up to now, only a homozygous pathogenic SV2A gene mutation was reported in human. We now report a novel heterozygous pathogenic SV2A gene mutation both in a girl and her mother result in epilepsy and poor response to LEV. Furthermore, the girl developed a new seizure type after using LEV. Our report had a clinical relevance that LEV could potentially produce contradictory efficacy in patients with SV2A gene mutation. If patients' seizures became exacerbated while using LEV, SV2A gene testing is recommended.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03038467193008
Publisher Site
http://dx.doi.org/10.1016/j.clineuro.2019.03.020DOI Listing
June 2019
4 Reads

Publication Analysis

Top Keywords

sv2a gene
20
gene mutation
16
seizure type
8
pathogenic sv2a
8
sv2a
6
lev
5
gene
5
response lev
4
poor response
4
lev girl
4
girl developed
4
developed seizure
4
reported human
4
epilepsy poor
4
result epilepsy
4
girl mother
4
heterozygous pathogenic
4
type lev
4
report novel
4
human report
4

Similar Publications